---
title: "Fmr LLC Trims Holdings in Glaukos Co. (NYSE:GKOS)"
description: "Fmr LLC reduced its stake in Glaukos Co. (NYSE:GKOS) by 7.2% in Q4, now holding 6,111,756 shares valued at $916.4 million. Other investors like Vanguard and State Street also adjusted their holdings. "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/235399361.md"
published_at: "2025-04-10T10:12:56.000Z"
---

# Fmr LLC Trims Holdings in Glaukos Co. (NYSE:GKOS)

> Fmr LLC reduced its stake in Glaukos Co. (NYSE:GKOS) by 7.2% in Q4, now holding 6,111,756 shares valued at $916.4 million. Other investors like Vanguard and State Street also adjusted their holdings. Glaukos shares opened at $85.87, with a market cap of $4.86 billion. The company reported a loss of $0.40 EPS, missing estimates. Insider trading included CFO Alex R. Thurman selling shares, and analysts have raised target prices for Glaukos, with Wells Fargo setting it at $160.00 and Stifel Nicolaus at $175.00.

Fmr LLC decreased its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 7.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,111,756 shares of the medical instruments supplier's stock after selling 472,732 shares during the period. Fmr LLC owned 11.08% of Glaukos worth $916,397,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in GKOS. Vanguard Group Inc. raised its holdings in shares of Glaukos by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier's stock valued at $895,887,000 after acquiring an additional 101,838 shares in the last quarter. State Street Corp lifted its position in Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock valued at $254,626,000 after purchasing an additional 98,109 shares during the last quarter. Geode Capital Management LLC grew its stake in Glaukos by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 1,197,215 shares of the medical instruments supplier's stock worth $179,555,000 after buying an additional 25,199 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Glaukos by 1,235.4% in the 4th quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock worth $122,374,000 after buying an additional 755,035 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of Glaukos during the 4th quarter valued at $121,390,000. Institutional investors own 99.04% of the company's stock.

## Glaukos Trading Up 2.7 %

Shares of GKOS opened at $85.87 on Tuesday. The firm has a fifty day simple moving average of $122.46 and a two-hundred day simple moving average of $134.38. Glaukos Co. has a twelve month low of $77.91 and a twelve month high of $163.71. The stock has a market capitalization of $4.86 billion, a P/E ratio of -29.92 and a beta of 0.88. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, research analysts anticipate that Glaukos Co. will post -1.08 EPS for the current year.

## Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.

## Analyst Upgrades and Downgrades

Several research analysts recently issued reports on GKOS shares. Wells Fargo & Company upped their target price on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Stifel Nicolaus upped their price objective on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, December 31st. Citigroup raised Glaukos from a "neutral" rating to a "buy" rating and raised their price objective for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. Piper Sandler reaffirmed an "overweight" rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Finally, Truist Financial increased their price target on shares of Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $163.25.

**View Our Latest Stock Report on Glaukos**

## Glaukos Profile

(Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

## Featured Stories

-   Five stocks we like better than Glaukos
-   Best Aerospace Stocks Investing
-   Options Activity Points to More Volatility for Palantir Stock
-   Value Investing: Is it a Good Strategy in 2022? Hint: Always
-   NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?
-   With Risk Tolerance, One Size Does Not Fit All
-   MicroStrategy Sees Insider Buy-Sell Action in Q1

**Want to see what other hedge funds are holding GKOS?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS - Free Report).

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Glaukos Right Now?

Before you consider Glaukos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.

While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [GKOS.US - Glaukos](https://longbridge.com/en/quote/GKOS.US.md)
- [WFC.US - Wells Fargo](https://longbridge.com/en/quote/WFC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Glaukos｜8-K：2025 财年 Q4 营收 1.43 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276168616.md) |
| 由于青光眼产品的销售，Glaukos 第四季度的收入有所增长 | Glaukos 报告第四季度收入同比增长 36%，主要得益于青光眼产品的强劲销售。然而，第四季度的调整后净亏损超出分析师预期。该公司重申其 2026 年净销售指导为 6 亿到 6.2 亿美元。尽管因产品过渡而产生了减值费用，Glaukos  | [Link](https://longbridge.com/en/news/276168646.md) |
| 在第四季度业绩公布后，这些分析师提高了对 Glaukos 的预测 | Glaukos Corp（纽约证券交易所代码：GKOS）报告第四季度每股亏损 28 美分，未能达到预期，但销售额为 1.431 亿美元，超出预期。公司确认 2026 财年的销售指导为 6 亿至 6.2 亿美元。首席执行官 Thomas Bu | [Link](https://longbridge.com/en/news/276242569.md) |
| 瑞穗证券重申其对 Glaukos（GKOS）的买入评级 | 瑞穗证券分析师安东尼·佩特罗尼（Anthony Petrone）重申了对 Glaukos（GKOS）的买入评级，股票收盘价为 121.00 美元。佩特罗尼是一位四星级分析师，平均回报率为 7.3%，成功率为 50.11%。市场对 Glauk | [Link](https://longbridge.com/en/news/276330855.md) |
| 专家展望：从 10 位分析师的视角看 Glaukos | 在过去三个月中，10 位分析师对 Glaukos（纽约证券交易所代码：GKOS）进行了评级，显示出看涨和看跌情绪的混合。12 个月的平均目标价为 134.8 美元，高于 121.50 美元，最高为 160.00 美元，最低为 116.00  | [Link](https://longbridge.com/en/news/276224230.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
